IBEX Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

IBEX Wealth Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-33,436	Closed	-$3.6M	–	209
2021 Q4	$3.6M	Buy	33,436 +672	+2%	+$73.3K	0.64%	60
2021 Q3	$3.59M	Buy	32,764 +856	+3%	+$88.9K	0.69%	61
2021 Q2	$2.99M	Sell	31,908 -1,226	-4%	-$113K	0.6%	69
2021 Q1	$3.05M	Buy	33,134 +5,577	+20%	+$471K	0.75%	60
2020 Q4	$2.02M	Buy	27,557 +4,719	+21%	+$351K	0.53%	71
2020 Q3	$1.77M	Buy	+22,838	New	+$1.57M	0.51%	68

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IBEX Wealth Advisors's HZNP Position: Q1 2022 in Review

IBEX Wealth Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 33,436 shares — an estimated $3.6M sold.

IBEX Wealth Advisors first reported a position in HZNP in Q3 2020 and held it in 6 quarters. The position peaked at $3.6M in Q4 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

IBEX Wealth Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
IBEX Wealth Advisors sold 33,436 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $3.6M.
IBEX Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 6 quarters.
IBEX Wealth Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.6M in Q4 2021.
620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on IBEX Wealth Advisors's 13F filing for Q1 2022, filed 16 May 2022.